UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research. More Confidence, More Insights, Less Sample Biomarker selection for Olink Target 48 Immune Surveillance were designed to give researchers the most effective platfo
Yahoo! Finance: OLK News